Printer's No. PN1949
See other bills
under the
same topic PRINTER'S NO. 1949 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE BILL No.1462 Session of 2026 INTRODUCED BY CAPPELLETTI, MUTH, KANE, TARTAGLIONE, HAYWOOD, COSTA AND L. WILLIAMS, SEPTEMBER 24, 2026 REFERRED TO CONSUMER PROTECTION AND PROFESSIONAL LICENSURE, SEPTEMBER 24, 2026 AN ACTAmending the act of September 27, 1961 (P.L.1700, No.699), entitled "An act relating to the regulation of the practice of pharmacy, including the sales, use and distribution of drugs and devices at retail; and amending, revising, consolidating and repealing certain laws relating thereto," further providing for definitions; providing for HIV infection prevention medication; and further providing for collaborative drug therapy management and for construction.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 2(11) and (14) of the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act, are amended and the section is amended by adding clauses to read:Section 2. Definitions.--As used in this act:* * *(11) "Practice of pharmacy" means the provision of health care services by a pharmacist, which includes the interpretation, evaluation and implementation of medical orders for the provision of pharmacy services or prescription drug orders; the delivery, dispensing or distribution of prescription 1234567891011121314151617181920 drugs; participation in drug and device selection; drug administration; drug regimen review; drug therapy management, including such services provided under the Medicare Prescription Drug, Improvements, and Modernization Act of 2003 (Public Law 108-173, 117 Stat. 2066); drug or drug-related research; compounding; proper and safe storage of drugs and devices; management of drug therapy pursuant to section 9.3 or, if in an institutional setting, consistent with the institution's assignment of clinical duties pursuant to a written agreement or protocol as set forth in section 9.1; the initiation, dispensing or administration of HIV infection prevention medication and related laboratory testing, assessment, referral and consultation under section 3.5; maintaining proper records; patient counseling; and such acts, services, operations or transactions necessary or incident to the provision of these health care services. The "practice of pharmacy" shall not include the operations of a manufacturer or distributor as defined in "The Controlled Substance, Drug, Device and Cosmetic Act."* * *(14) "Management of drug therapy" means any of the following processes which shall be performed pursuant to a written agreement or protocol as set forth in section 9.1 or pursuant to section 9.3 or, in the case of HIV infection prevention medication, under section 3.5: adjusting a drug regimen; adjusting drug strength, frequency of administration or route; administration of drugs; ordering laboratory tests and ordering and performing other diagnostic tests necessary in the management of drug therapy; monitoring the patient's vital signs; and providing education and training to the patient which 20260SB1462PN1949 - 2 - 123456789101112131415161718192021222324252627282930 is related to the management of drug therapy. The management of drug therapy under section 9.1 shall be performed consistent with the institution's assignment of clinical duties, and ordering of laboratory tests and ordering or performing other diagnostic tests necessary in the management of drug therapy shall be consistent with the testing standards of the institution.* * *(26) "HIV" means the human immunodeficiency virus.(27) "HIV infection prevention medication" means preexposure prophylaxis HIV medication, postexposure prophylaxis HIV medication or another drug or drug combination approved by the United States Food and Drug Administration that may be used to prevent HIV infection.(28) "Postexposure prophylaxis HIV medication" means a drug or drug combination approved by the United States Food and Drug Administration that may be taken after potential exposure to HIV to prevent HIV infection.(29) "Preexposure prophylaxis HIV medication" means a drug or drug combination approved by the United States Food and Drug Administration that may be taken before potential exposure to HIV to prevent HIV infection.Section 2. The act is amended by adding a section to read:Section 3.5. HIV Infection Prevention Medication.--(a) A pharmacist may initiate, dispense or administer HIV infection prevention medication without a prescription in accordance with the Statewide drug therapy protocol and practice guidelines established under subsection (b) and the applicable requirements specified under subsection (c).(b) The board shall promulgate regulati ons establishing a 20260SB1462PN1949 - 3 - 123456789101112131415161718192021222324252627282930 Statewide drug therapy protocol and practice guidelines under which a pharmacist may initiate, dispense or administer HIV infection prevention medication. The protocol and guidelines shall include all of the following:(1) Satisfactory completion of a curriculum or training program approved by the board and offered by a provider accredited by the Accreditation Council for Pharmacy Education. The curriculum or training program must relate to the initiation, dispensing or administration of HIV infection prevention medication and related laboratory testing, assessment, referral and consultation.(2) Maintenance of professional liability insurance coverage in the minimum amount of one million dollars ($1,000,000) per occurrence or claims made. Failure to maintain insurance coverage as required under this paragraph shall be actionable under section 5. The board shall accept any of the following as satisfactory evidence of insurance coverage:(i) Personally purchased professional liability insurance.(ii) Professional liability insurance coverage provided by the pharmacist's employer.(iii) Similar insurance coverage acceptable to the board.(3) The pharmacist shall determine the minimum quantity of preexposure prophylaxis HIV medication necessary for an initial supply. The pharmacist may not dispense an initial supply of preexposure prophylaxis HIV medication to the same patient more than once every two years unless a medical practitioner authorized by law to prescribe preexposure prophylaxis HIV medication directs otherwise. To receive a subsequent prescription for preexposure prophylaxis HIV medication, the patient shall consult with a medical practitioner authorized by 20260SB1462PN1949 - 4 - 123456789101112131415161718192021222324252627282930 law to prescribe preexposure prophylaxis HIV medication.(4) A pharmacist may initiate, dispense or administer preexposure prophylaxis HIV medication only if all of the following apply:(i) The patient is HIV negative, as documented by a negative test result obtained within the previous seven days using an HIV antigen/antibody test, an HIV antibody-only test or a rapid, point-of-care fingerstick blood test approved by the United States Food and Drug Administration. If the patient does not provide evidence of a negative test result in accordance with this subclause, the pharmacist shall order an HIV-related test. If the test result is not transmitted directly to the pharmacist, the pharmacist shall verify the test result to the pharmacist's satisfaction. If the patient tests positive for HIV infection, the pharmacist shall refer the patient to a medical practitioner or clinic that provides primary care or HIV care and provide the patient with a list of medical practitioners and clinics in the region that provide primary care or HIV care.(ii) The patient does not report any sign or symptom of acute HIV infection on a self-reported checklist of signs and symptoms of acute HIV infection.(iii) The patient does not report taking medication that is contraindicated for use with the preexposure prophylaxis HIV medication.(iv) The pharmacist provides counseling to the patient regarding the ongoing use of the preexposure prophylaxis HIV medication. The counseling may include education regarding side effects, safety during pregnancy and breastfeeding, adherence to recommended dosing and the importance of timely testing and treatment, as applicable, for HIV, renal function, hepatitis B, 20260SB1462PN1949 - 5 - 123456789101112131415161718192021222324252627282930 hepatitis C, sexually transmitted infection and pregnancy for an individual of childbearing capacity.(v) The pharmacist notifies the patient of all of the following:(A) The patient must consult with a medical practitioner authorized by law to prescribe preexposure prophylaxis HIV medication to receive a subsequent prescription for the medication.(B) A pharmacist may not dispense an initial supply of preexposure prophylaxis HIV medication to the same patient more than once every two years unless a medical practitioner authorized by law to prescribe preexposure prophylaxis HIV medication directs otherwise.(vi) The pharmacist documents, to the extent possible, the services provided by the pharmacist in the patient's record in the record system maintained by the pharmacy. The pharmacist shall maintain a record of preexposure prophylaxis HIV medication dispensed or administered to each patient.(5) A pharmacist may initiate, dispense or administer a complete course of postexposure prophylaxis HIV medication only if all of the following apply:(i) The pharmacist screens the patient and determines that the potential exposure to HIV occurred within the previous seventy-two hours and that the patient otherwise meets the clinical criteria for postexposure prophylaxis HIV medication under the CDC guidelines.(ii) The pharmacist orders or performs an HIV-related test in accordance with subsection (c) or determines that the patient is willing to undergo an HIV-related test consistent with the CDC guidelines. If the patient refuses to undergo an HIV-related 20260SB1462PN1949 - 6 - 123456789101112131415161718192021222324252627282930 test but is otherwise eligible for postexposure prophylaxis HIV medication under this section, the pharmacist may initiate, dispense or administer the medication.(iii) The pharmacist provides counseling to the patient regarding the use of the postexposure prophylaxis HIV medication consistent with the CDC guidelines. The counseling may include education regarding side effects, safety during pregnancy and breastfeeding, adherence to recommended dosing and the importance of timely testing and treatment, as applicable, for HIV and sexually transmitted infection. The pharmacist shall also inform the patient of the availability of preexposure prophylaxis HIV medication for an individual who is at substantial risk of acquiring HIV.(iv) If the patient identifies a medical practitioner who provides primary care to the patient and consents to notification, the pharmacist shall notify the medical practitioner within forty-eight hours after initiating, dispensing or administering the postexposure prophylaxis HIV medication. The pharmacist shall inform the patient of the notification requirement before initiating, dispensing or administering the medication.(v) The pharmacist documents, to the extent possible, the services provided by the pharmacist in the patient's record in the record system maintained by the pharmacy. The pharmacist shall maintain a record of postexposure prophylaxis HIV medication dispensed or administered to each patient.(c) The following shall apply to HIV-related tests necessary to provide service under this section:(1) A pharmacist may order an HIV-related test necessary to provide services under this section.20260SB1462PN1949 - 7 - 123456789101112131415161718192021222324252627282930 (2) A pharmacist may perform an HIV-related test under this section only if all of the following apply:(i) The pharmacy holds a valid certificate of waiver issued by the Centers for Medicare and Medicaid Services.(ii) The test is authorized or approved by the United States Food and Drug Administration and classified as waived under the Clinical Laboratory Improvement Amendments of 1988 (Public Law 100-578, 102 Stat. 2903).(iii) The pharmacist complies with applicable Federal and State law governing HIV-related testing.(3) A pharmacy or pharmacist that performs an HIV-related test in accordance with this subsection shall be exempt from the requirements under section 3 of the act of September 26, 1951 (P.L.1539, No.389), known as "The Clinical Laboratory Act," with respect to the HIV-related test.(4) A pharmacist who orders or performs an HIV-related test under this section shall comply with the act of November 29, 1990 (P.L.585, No.148), known as the "Confidentiality of HIV-Related Information Act," including the requirements relating to informed consent, confirmatory testing, notice of test results, posttest counseling and confidentiality.(d) The following shall apply to the promulgation of regulations under this section:(1) In order to facilitate the prompt implementation of this section, the board shall promulgate temporary regulations that shall expire no later than two years following the publication of the temporary regulations. The board shall submit the temporary regulations to the Legislative Reference Bureau for publication in the next available issue of the Pennsylvania Bulletin and post the temporary regulations on the board's 20260SB1462PN1949 - 8 - 123456789101112131415161718192021222324252627282930 publicly accessible Internet website within six months after the effective date of this paragraph. The board may promulgate temporary regulations not subject to:(i) Sections 201, 202, 203, 204 and 205 of the act of July 31, 1968 (P.L.769, No.240), referred to as the Commonwealth Documents Law.(ii) Sections 204(b) and 301(10) of the act of October 15, 1980 (P.L.950, No.164), known as the Commonwealth Attorneys Act.(iii) The act of June 25, 1982 (P.L.633, No.181), known as the Regulatory Review Act.(2) The board's authority to promulgate temporary regulations under paragraph (1) shall expire two years after the publication of the temporary regulations. Regulations promulgated after this period shall be promulgated as provided by law.(e) As used in this section, the follow ing words and phrases shall have the meanings given to them in this subsection unless the context clearly indicates otherwise:(1) "CDC guidelines" means the guidelines published by the Centers for Disease Control and Prevention in "Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025" and subsequent guidelines approved by the board. The board shall transmit notice of the approval of subsequent guidelines to the Legislative Reference Bureau for publication in the next available issue of the Pennsylvania Bulletin.(2) "HIV-related test" means the term as defined in section 3 of the "Confidentiality of HIV-Related Information Act."Section 3. Sections 9.3(a) and 9.4 of the act are amended to 20260SB1462PN1949 - 9 - 123456789101112131415161718192021222324252627282930 read:Section 9.3. Collaborative Drug Therapy Management.--(a) [A] Except as provided under section 3.5, a pharmacist shall enter into a written collaborative agreement with a licensed physician authorizing the management of drug therapy for a disease or for a condition or symptom of a disease before practicing the management of drug therapy in a setting other than an institutional setting.* * *Section 9.4. Construction.--[Nothing] Except as provided under section 3.5, nothing in this act shall be construed to provide prescriptive authority to a pharmacist.Section 4. This act shall take effect immediately.20260SB1462PN1949 - 10 - 12345678910111213
under the
same topic PRINTER'S NO. 1949 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE BILL No.1462 Session of 2026 INTRODUCED BY CAPPELLETTI, MUTH, KANE, TARTAGLIONE, HAYWOOD, COSTA AND L. WILLIAMS, SEPTEMBER 24, 2026 REFERRED TO CONSUMER PROTECTION AND PROFESSIONAL LICENSURE, SEPTEMBER 24, 2026 AN ACTAmending the act of September 27, 1961 (P.L.1700, No.699), entitled "An act relating to the regulation of the practice of pharmacy, including the sales, use and distribution of drugs and devices at retail; and amending, revising, consolidating and repealing certain laws relating thereto," further providing for definitions; providing for HIV infection prevention medication; and further providing for collaborative drug therapy management and for construction.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 2(11) and (14) of the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act, are amended and the section is amended by adding clauses to read:Section 2. Definitions.--As used in this act:* * *(11) "Practice of pharmacy" means the provision of health care services by a pharmacist, which includes the interpretation, evaluation and implementation of medical orders for the provision of pharmacy services or prescription drug orders; the delivery, dispensing or distribution of prescription 1234567891011121314151617181920 drugs; participation in drug and device selection; drug administration; drug regimen review; drug therapy management, including such services provided under the Medicare Prescription Drug, Improvements, and Modernization Act of 2003 (Public Law 108-173, 117 Stat. 2066); drug or drug-related research; compounding; proper and safe storage of drugs and devices; management of drug therapy pursuant to section 9.3 or, if in an institutional setting, consistent with the institution's assignment of clinical duties pursuant to a written agreement or protocol as set forth in section 9.1; the initiation, dispensing or administration of HIV infection prevention medication and related laboratory testing, assessment, referral and consultation under section 3.5; maintaining proper records; patient counseling; and such acts, services, operations or transactions necessary or incident to the provision of these health care services. The "practice of pharmacy" shall not include the operations of a manufacturer or distributor as defined in "The Controlled Substance, Drug, Device and Cosmetic Act."* * *(14) "Management of drug therapy" means any of the following processes which shall be performed pursuant to a written agreement or protocol as set forth in section 9.1 or pursuant to section 9.3 or, in the case of HIV infection prevention medication, under section 3.5: adjusting a drug regimen; adjusting drug strength, frequency of administration or route; administration of drugs; ordering laboratory tests and ordering and performing other diagnostic tests necessary in the management of drug therapy; monitoring the patient's vital signs; and providing education and training to the patient which 20260SB1462PN1949 - 2 - 123456789101112131415161718192021222324252627282930 is related to the management of drug therapy. The management of drug therapy under section 9.1 shall be performed consistent with the institution's assignment of clinical duties, and ordering of laboratory tests and ordering or performing other diagnostic tests necessary in the management of drug therapy shall be consistent with the testing standards of the institution.* * *(26) "HIV" means the human immunodeficiency virus.(27) "HIV infection prevention medication" means preexposure prophylaxis HIV medication, postexposure prophylaxis HIV medication or another drug or drug combination approved by the United States Food and Drug Administration that may be used to prevent HIV infection.(28) "Postexposure prophylaxis HIV medication" means a drug or drug combination approved by the United States Food and Drug Administration that may be taken after potential exposure to HIV to prevent HIV infection.(29) "Preexposure prophylaxis HIV medication" means a drug or drug combination approved by the United States Food and Drug Administration that may be taken before potential exposure to HIV to prevent HIV infection.Section 2. The act is amended by adding a section to read:Section 3.5. HIV Infection Prevention Medication.--(a) A pharmacist may initiate, dispense or administer HIV infection prevention medication without a prescription in accordance with the Statewide drug therapy protocol and practice guidelines established under subsection (b) and the applicable requirements specified under subsection (c).(b) The board shall promulgate regulati ons establishing a 20260SB1462PN1949 - 3 - 123456789101112131415161718192021222324252627282930 Statewide drug therapy protocol and practice guidelines under which a pharmacist may initiate, dispense or administer HIV infection prevention medication. The protocol and guidelines shall include all of the following:(1) Satisfactory completion of a curriculum or training program approved by the board and offered by a provider accredited by the Accreditation Council for Pharmacy Education. The curriculum or training program must relate to the initiation, dispensing or administration of HIV infection prevention medication and related laboratory testing, assessment, referral and consultation.(2) Maintenance of professional liability insurance coverage in the minimum amount of one million dollars ($1,000,000) per occurrence or claims made. Failure to maintain insurance coverage as required under this paragraph shall be actionable under section 5. The board shall accept any of the following as satisfactory evidence of insurance coverage:(i) Personally purchased professional liability insurance.(ii) Professional liability insurance coverage provided by the pharmacist's employer.(iii) Similar insurance coverage acceptable to the board.(3) The pharmacist shall determine the minimum quantity of preexposure prophylaxis HIV medication necessary for an initial supply. The pharmacist may not dispense an initial supply of preexposure prophylaxis HIV medication to the same patient more than once every two years unless a medical practitioner authorized by law to prescribe preexposure prophylaxis HIV medication directs otherwise. To receive a subsequent prescription for preexposure prophylaxis HIV medication, the patient shall consult with a medical practitioner authorized by 20260SB1462PN1949 - 4 - 123456789101112131415161718192021222324252627282930 law to prescribe preexposure prophylaxis HIV medication.(4) A pharmacist may initiate, dispense or administer preexposure prophylaxis HIV medication only if all of the following apply:(i) The patient is HIV negative, as documented by a negative test result obtained within the previous seven days using an HIV antigen/antibody test, an HIV antibody-only test or a rapid, point-of-care fingerstick blood test approved by the United States Food and Drug Administration. If the patient does not provide evidence of a negative test result in accordance with this subclause, the pharmacist shall order an HIV-related test. If the test result is not transmitted directly to the pharmacist, the pharmacist shall verify the test result to the pharmacist's satisfaction. If the patient tests positive for HIV infection, the pharmacist shall refer the patient to a medical practitioner or clinic that provides primary care or HIV care and provide the patient with a list of medical practitioners and clinics in the region that provide primary care or HIV care.(ii) The patient does not report any sign or symptom of acute HIV infection on a self-reported checklist of signs and symptoms of acute HIV infection.(iii) The patient does not report taking medication that is contraindicated for use with the preexposure prophylaxis HIV medication.(iv) The pharmacist provides counseling to the patient regarding the ongoing use of the preexposure prophylaxis HIV medication. The counseling may include education regarding side effects, safety during pregnancy and breastfeeding, adherence to recommended dosing and the importance of timely testing and treatment, as applicable, for HIV, renal function, hepatitis B, 20260SB1462PN1949 - 5 - 123456789101112131415161718192021222324252627282930 hepatitis C, sexually transmitted infection and pregnancy for an individual of childbearing capacity.(v) The pharmacist notifies the patient of all of the following:(A) The patient must consult with a medical practitioner authorized by law to prescribe preexposure prophylaxis HIV medication to receive a subsequent prescription for the medication.(B) A pharmacist may not dispense an initial supply of preexposure prophylaxis HIV medication to the same patient more than once every two years unless a medical practitioner authorized by law to prescribe preexposure prophylaxis HIV medication directs otherwise.(vi) The pharmacist documents, to the extent possible, the services provided by the pharmacist in the patient's record in the record system maintained by the pharmacy. The pharmacist shall maintain a record of preexposure prophylaxis HIV medication dispensed or administered to each patient.(5) A pharmacist may initiate, dispense or administer a complete course of postexposure prophylaxis HIV medication only if all of the following apply:(i) The pharmacist screens the patient and determines that the potential exposure to HIV occurred within the previous seventy-two hours and that the patient otherwise meets the clinical criteria for postexposure prophylaxis HIV medication under the CDC guidelines.(ii) The pharmacist orders or performs an HIV-related test in accordance with subsection (c) or determines that the patient is willing to undergo an HIV-related test consistent with the CDC guidelines. If the patient refuses to undergo an HIV-related 20260SB1462PN1949 - 6 - 123456789101112131415161718192021222324252627282930 test but is otherwise eligible for postexposure prophylaxis HIV medication under this section, the pharmacist may initiate, dispense or administer the medication.(iii) The pharmacist provides counseling to the patient regarding the use of the postexposure prophylaxis HIV medication consistent with the CDC guidelines. The counseling may include education regarding side effects, safety during pregnancy and breastfeeding, adherence to recommended dosing and the importance of timely testing and treatment, as applicable, for HIV and sexually transmitted infection. The pharmacist shall also inform the patient of the availability of preexposure prophylaxis HIV medication for an individual who is at substantial risk of acquiring HIV.(iv) If the patient identifies a medical practitioner who provides primary care to the patient and consents to notification, the pharmacist shall notify the medical practitioner within forty-eight hours after initiating, dispensing or administering the postexposure prophylaxis HIV medication. The pharmacist shall inform the patient of the notification requirement before initiating, dispensing or administering the medication.(v) The pharmacist documents, to the extent possible, the services provided by the pharmacist in the patient's record in the record system maintained by the pharmacy. The pharmacist shall maintain a record of postexposure prophylaxis HIV medication dispensed or administered to each patient.(c) The following shall apply to HIV-related tests necessary to provide service under this section:(1) A pharmacist may order an HIV-related test necessary to provide services under this section.20260SB1462PN1949 - 7 - 123456789101112131415161718192021222324252627282930 (2) A pharmacist may perform an HIV-related test under this section only if all of the following apply:(i) The pharmacy holds a valid certificate of waiver issued by the Centers for Medicare and Medicaid Services.(ii) The test is authorized or approved by the United States Food and Drug Administration and classified as waived under the Clinical Laboratory Improvement Amendments of 1988 (Public Law 100-578, 102 Stat. 2903).(iii) The pharmacist complies with applicable Federal and State law governing HIV-related testing.(3) A pharmacy or pharmacist that performs an HIV-related test in accordance with this subsection shall be exempt from the requirements under section 3 of the act of September 26, 1951 (P.L.1539, No.389), known as "The Clinical Laboratory Act," with respect to the HIV-related test.(4) A pharmacist who orders or performs an HIV-related test under this section shall comply with the act of November 29, 1990 (P.L.585, No.148), known as the "Confidentiality of HIV-Related Information Act," including the requirements relating to informed consent, confirmatory testing, notice of test results, posttest counseling and confidentiality.(d) The following shall apply to the promulgation of regulations under this section:(1) In order to facilitate the prompt implementation of this section, the board shall promulgate temporary regulations that shall expire no later than two years following the publication of the temporary regulations. The board shall submit the temporary regulations to the Legislative Reference Bureau for publication in the next available issue of the Pennsylvania Bulletin and post the temporary regulations on the board's 20260SB1462PN1949 - 8 - 123456789101112131415161718192021222324252627282930 publicly accessible Internet website within six months after the effective date of this paragraph. The board may promulgate temporary regulations not subject to:(i) Sections 201, 202, 203, 204 and 205 of the act of July 31, 1968 (P.L.769, No.240), referred to as the Commonwealth Documents Law.(ii) Sections 204(b) and 301(10) of the act of October 15, 1980 (P.L.950, No.164), known as the Commonwealth Attorneys Act.(iii) The act of June 25, 1982 (P.L.633, No.181), known as the Regulatory Review Act.(2) The board's authority to promulgate temporary regulations under paragraph (1) shall expire two years after the publication of the temporary regulations. Regulations promulgated after this period shall be promulgated as provided by law.(e) As used in this section, the follow ing words and phrases shall have the meanings given to them in this subsection unless the context clearly indicates otherwise:(1) "CDC guidelines" means the guidelines published by the Centers for Disease Control and Prevention in "Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025" and subsequent guidelines approved by the board. The board shall transmit notice of the approval of subsequent guidelines to the Legislative Reference Bureau for publication in the next available issue of the Pennsylvania Bulletin.(2) "HIV-related test" means the term as defined in section 3 of the "Confidentiality of HIV-Related Information Act."Section 3. Sections 9.3(a) and 9.4 of the act are amended to 20260SB1462PN1949 - 9 - 123456789101112131415161718192021222324252627282930 read:Section 9.3. Collaborative Drug Therapy Management.--(a) [A] Except as provided under section 3.5, a pharmacist shall enter into a written collaborative agreement with a licensed physician authorizing the management of drug therapy for a disease or for a condition or symptom of a disease before practicing the management of drug therapy in a setting other than an institutional setting.* * *Section 9.4. Construction.--[Nothing] Except as provided under section 3.5, nothing in this act shall be construed to provide prescriptive authority to a pharmacist.Section 4. This act shall take effect immediately.20260SB1462PN1949 - 10 - 12345678910111213
Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.